Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.
2.
3.

The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas.

O'Connor OA.

Curr Treat Options Oncol. 2004 Aug;5(4):269-81. Review.

PMID:
15233904
4.

Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.

Leonard JP, Furman RR, Coleman M.

Int J Cancer. 2006 Sep 1;119(5):971-9. Review.

5.

Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.

Alinari L, White VL, Earl CT, Ryan TP, Johnston JS, Dalton JT, Ferketich AK, Lai R, Lucas DM, Porcu P, Blum KA, Byrd JC, Baiocchi RA.

MAbs. 2009 Jan-Feb;1(1):31-40.

6.

Proteasome inhibitors in the treatment of B-cell malignancies.

Schenkein D.

Clin Lymphoma. 2002 Jun;3(1):49-55. Review.

PMID:
12141956
7.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD.

J Clin Oncol. 2005 Feb 1;23(4):676-84. Epub 2004 Dec 21.

8.

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.

Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA.

Cancer. 2011 Jun 1;117(11):2442-51. doi: 10.1002/cncr.25792. Epub 2010 Dec 14.

9.

Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP.

Curr Cancer Drug Targets. 2011 Mar;11(3):239-53. Review.

10.

Proteasome inhibitors in mantle cell lymphoma.

Holkova B, Grant S.

Best Pract Res Clin Haematol. 2012 Jun;25(2):133-41. doi: 10.1016/j.beha.2012.04.007. Epub 2012 May 16. Review.

11.

Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.

Bogner C, Peschel C, Decker T.

Leuk Lymphoma. 2006 Feb;47(2):195-205. Review.

PMID:
16321849
12.

Discovery, Development, and clinical applications of bortezomib.

Jung L, Holle L, Dalton WS.

Oncology (Williston Park). 2004 Dec;18(14 Suppl 11):4-13. Review.

13.

Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.

O'Connor O, Wright J, Moskowitz CH, Muzzy J, MacGregor-Cortelli B, Hamlin P, Straus D, Trehu E, Schenkein DP, Zelenetz AD.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S21-2.

PMID:
19791425
14.

Bortezomib for the treatment of non-Hodgkin's lymphoma.

Bose P, Batalo MS, Holkova B, Grant S.

Expert Opin Pharmacother. 2014 Nov;15(16):2443-59. doi: 10.1517/14656566.2014.965142. Epub 2014 Sep 29. Review.

PMID:
25263936
15.

Use of bortezomib in B-cell non-Hodgkin's lymphoma.

Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J.

Expert Rev Anticancer Ther. 2006 Jul;6(7):983-91. Review.

PMID:
16831071
16.

The role of bortezomib in the treatment of lymphoma.

Barr P, Fisher R, Friedberg J.

Cancer Invest. 2007 Dec;25(8):766-75. Review.

PMID:
18058474
17.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM.

J Clin Oncol. 2005 Feb 1;23(4):667-75. Epub 2004 Dec 21.

18.

Proteasome inhibitor, bortezomib, for myeloma and lymphoma.

Tobinai K.

Int J Clin Oncol. 2007 Oct;12(5):318-26. Epub 2007 Oct 22. Review.

PMID:
17929113
19.

Novel proteasome inhibitors to overcome bortezomib resistance.

Ruschak AM, Slassi M, Kay LE, Schimmer AD.

J Natl Cancer Inst. 2011 Jul 6;103(13):1007-17. doi: 10.1093/jnci/djr160. Epub 2011 May 23. Review.

20.

Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.

Koprivnikar JL, Cheson BD.

Future Oncol. 2012 Apr;8(4):359-71. doi: 10.2217/fon.12.23.

PMID:
22515439
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk